|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 31/519 | (2006.01) |
| A61P 37/00 | (2006.01) |
| (11) | Number of the document | 3285772 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16719356.4 |
| Date of filing the European patent application | 2016-04-20 | |
| (97) | Date of publication of the European application | 2018-02-28 |
| (45) | Date of publication and mention of the grant of the patent | 2019-10-02 |
| (46) | Date of publication of the claims translation | 2020-01-10 |
| (86) | Number | PCT/EP2016/058810 |
| Date | 2016-04-20 |
| (87) | Number | WO 2016/170014 |
| Date | 2016-10-27 |
| (30) | Number | Date | Country code |
| 201506786 | 2015-04-21 | GB |
| (72) |
ALLEN, Rodger Anthony, GB
BARONE, Francesca, GB
FAHY, William Anthony, GB
NAYAR, Saba, GB
|
| (73) |
UCB Biopharma SRL,
Allée de la Recherche 60, 1070 Brussels,
BE
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Specifinis trifluoroetilkinolino analogas, naudojamas Sjögreno sindromo gydymui |
| A SPECIFIC TRIFLUOROETHYL QUINOLINE ANALOGUE FOR USE IN THE TREATMENT OF SJÖGREN`S SYNDROME |
| Payment date | Validity (years) | Amount | |
| 2024-04-03 | 9 | 208.00 EUR |
| 2025-04-20 |